Kiniksa Pharmaceuticals, Ltd. Book Value | KNSA

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Kiniksa Pharmaceuticals, Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
568 M	438 M	439 M	396 M	185 M	312 M	225 M	279 M	-89.7 M	-25.7 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
568 M	-89.7 M	273 M

Quarterly Book Value Kiniksa Pharmaceuticals, Ltd.

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
606 M	535 M	495 M	457 M	437 M	435 M	432 M	405 M	412 M	390 M	396 M	384 M	-	166 M	185 M	214 M	236 M	271 M	312 M	312 M	312 M	312 M	225 M	225 M	225 M	225 M	279 M	279 M	279 M	279 M	30.1 M	30.1 M	30.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
606 M	30.1 M	307 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
AnaptysBio ANAB	317 M	$ 51.0	1.83 %	$ 1.48 B	USA
Allakos ALLK	78.8 M	-	-	$ 28.6 M	USA
Black Diamond Therapeutics BDTX	112 M	$ 1.88	0.53 %	$ 107 M	USA
Clovis Oncology CLVS	-279 M	-	-7.23 %	$ 13 M	USA
Concert Pharmaceuticals CNCE	112 M	-	-	$ 401 M	USA
Evelo Biosciences EVLO	-4.99 M	-	-14.46 %	$ 27.9 M	USA
BioMarin Pharmaceutical BMRN	6.09 B	$ 60.26	0.06 %	$ 11.6 B	USA
BioNTech SE BNTX	19.2 B	$ 98.52	0.24 %	$ 23.8 B	Germany
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 2.17	0.46 %	$ 3.57 M	Israel
Freeline Therapeutics Holdings plc FRLN	52.4 M	-	-	$ 384 M	Britain
Genocea Biosciences GNCA	27.1 M	-	-15.0 %	$ 3.04 M	USA
Catalyst Biosciences CBIO	142 M	$ 13.99	0.84 %	$ 1.25 B	USA
C4 Therapeutics CCCC	257 M	$ 2.98	0.3 %	$ 247 M	USA
Codexis CDXS	50.5 M	$ 1.32	1.09 %	$ 115 M	USA
Amryt Pharma plc AMYT	357 M	-	-	$ 621 M	Britain
Cerus Corporation CERS	65 M	$ 2.62	0.38 %	$ 499 M	USA
G1 Therapeutics GTHX	35.4 M	-	-	$ 370 M	USA
Coherus BioSciences CHRS	61 M	$ 1.13	0.43 %	$ 132 M	USA
Celldex Therapeutics CLDX	527 M	$ 31.1	1.16 %	$ 2.07 B	USA
CollPlant Biotechnologies Ltd. CLGN	6.08 M	$ 4.25	3.16 %	$ 51.9 M	Israel
Cellectar Biosciences CLRB	9.92 M	$ 1.8	0.72 %	$ 4.69 M	USA
AbbVie ABBV	134 B	$ 264.34	0.09 %	$ 468 B	USA
Humanigen HGEN	-46.8 M	-	-81.12 %	$ 4.28 M	USA
Cocrystal Pharma COCP	6.33 M	$ 1.17	1.74 %	$ 13.2 M	USA
AbCellera Biologics ABCL	967 M	$ 12.7	0.4 %	$ 3.79 B	Canada
Abeona Therapeutics ABEO	159 M	$ 5.4	2.65 %	$ 286 M	USA
Collegium Pharmaceutical COLL	302 M	$ 22.53	0.2 %	$ 713 M	USA
Corcept Therapeutics Incorporated CORT	648 M	$ 116.1	4.93 %	$ 12.1 B	USA
Фармсинтез LIFE	29.8 B	-	-	-	Russia
IGM Biosciences IGMS	48.2 M	-	-	$ 76.9 M	USA
IMV IMV	-6.6 M	-	-	$ 13.1 M	Canada
Kinnate Biopharma KNTE	159 M	-	-	$ 123 M	USA
Cardiff Oncology CRDF	45.4 M	$ 1.24	0.74 %	$ 82.9 M	USA
Checkmate Pharmaceuticals CMPI	69.5 M	-	-	$ 231 M	USA
Corbus Pharmaceuticals Holdings CRBP	148 M	$ 7.14	0.19 %	$ 95.1 M	USA
Karuna Therapeutics KRTX	1.25 B	-	-	$ 12.2 B	USA
Curis CRIS	5.46 M	$ 0.83	1.1 %	$ 10.9 M	USA
CorMedix CRMD	405 M	$ 7.85	1.03 %	$ 565 K	USA
Crinetics Pharmaceuticals CRNX	992 M	$ 84.95	0.13 %	$ 7.99 B	USA
CRISPR Therapeutics AG CRSP	1.92 B	$ 54.23	0.23 %	$ 4.88 B	Schweiz
Champions Oncology CSBR	4.07 M	$ 4.9	0.1 %	$ 67.8 M	USA
Chimerix CMRX	122 M	-	-	$ 756 M	USA
Corvus Pharmaceuticals CRVS	61.2 M	$ 11.62	8.21 %	$ 918 M	USA
Cue Biopharma CUE	26.4 M	$ 31.41	1.45 %	$ 2.98 B	USA
CEL-SCI Corporation CVM	16 M	$ 1.67	2.38 %	$ 13.4 M	USA
Arbutus Biopharma Corporation ABUS	76.6 M	$ 4.85	0.2 %	$ 929 M	Canada
Cytokinetics, Incorporated CYTK	-660 M	$ 64.66	0.17 %	$ 7.77 M	USA
Daré Bioscience DARE	2.84 M	$ 0.78	4.73 %	$ 8.72 M	USA
Adagene ADAG	51.9 M	$ 2.93	2.86 %	$ 173 M	China
DiaMedica Therapeutics DMAC	61.4 M	$ 7.94	1.4 %	$ 373 M	USA